Comparison of effects of methotrexate/calcium folinate and actinomycin D on trophoblastic tumors

Reference

• Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. 2012. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 12(12):CD008891.
   Google Scholar
• Chen N, Hematology DO, Hospital XC. 2017. Different administration routes of calcium folinate on the prevention of oral mucositis in children with acute lymphoblastic leukemia. J Clin Nurs Pract. 38:10–11.
   Google Scholar
• Claxton L, Taylor M, Soonasra A, Bourret JA, Gerber RA. 2018. An economic evaluation of tofacitinib treatment in rheumatoid arthritis after methotrexate or after 1 or 2 TNF inhibitors from a U.S. payer perspective. Eur J Med Chem. 138:170–181.
   Google Scholar
• Cortes CL, Veiga SR, Almacellas E, Hernándezlosa J, Ferreres JC, Kozma SC, Ambrosio S, Thomas G, Tauler A. 2016. Effect of low doses of actinomycin D on neuroblastoma cell lines. Mol Cancer. 15(1):1–13.
   Google Scholar
• Elias KM, Harvey RA, Hasselblatt KT, Seckl MJ, Berkowitz RS. 2014. Type I interferons modulate methotrexate resistance in gestational trophoblastic neoplasia. Gynecol Oncol. 133(6):190–191.
   Google Scholar
• Eysbouts YK, Ottevanger PB, Lfag M, Inthout J, Short D, Harvey R, Kaur B, Sebire NJ, Sarwar N, Fcgj S. 2017. Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset. Ann Oncol. 28(8):1856–1861.
   Web of Science ®Google Scholar
• Fan S, Pan M, Qin H. 2015. The relationship between the expression of β-HCG mRNA in peripheral blood and the hematogenous metastasis of gestational trophoblastic neoplasia. Pract J Cancer. 6:25–28.
   Google Scholar
• Fujieda M, Tsuruga K, Sato T, Kikuchi H, Tamaki W, Ishihara M, Yamamoto M, Oishi T, Tanaka H, Daibata M. 2016. Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab. Mod Rheumatol. 27(1):66–71.
   Web of Science ®Google Scholar
• Guzel AI, Kokanali MK, Erkilinc S, Topcu HO, Oz M, Ozgu E, Erkaya S, Gungor T. 2014. Predictive role of the neutrophil lymphocyte ratio for invasion with gestational trophoblastic disease. Asian Pac J Cancer Prev. 15(10):4203–4206.
   PubMedGoogle Scholar
• Hsieh FJ, Wu CC, Lee CN, Chen TM, Chen CA, Chen FC, Chen CL, Hsieh CY. 2015. Vascular patterns of gestational trophoblastic tumors by color Doppler ultrasound. Cancer. 74(8):2361–2365.
   Google Scholar
• Jiang F, Wan X-R, Xu T, Feng F-Z, Ren T, Yang J-J, Zhao J, Yang T, Yjgo X. 2018. Evaluation and suggestions for improving the FIGO 2000 staging criteria for gestational trophoblastic neoplasia: A ten-year review of 1420 patients. Gynecol Oncol. 149(3):539–544.
   PubMed Web of Science ®Google Scholar
• Kang H, Zhao Q, Yang S, Duan W, Oncology DO. 2017. A prospective study of actinomycin D combined with methotrexate and methotrexate only in the treatment of low-risk gestational trophoblastic tumor. Beijing Med J. 11(3):199–201.
   Google Scholar
• Kanno T, Matsui H, Akizawa Y, Usui H, Shozu M. 2018. Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide. J Gynecol Oncol. 29(6):e89.
   Web of Science ®Google Scholar
• Li J, Li S, Yu H, Wang J, Xu C, Lu X. 2018. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis. Gynecol Oncol. 148(2):247–253.
   Web of Science ®Google Scholar
• Lu WG, Ding ZM, Xie X, Ye DF, Chen HZ, Feng SW. 2003. [Single methotrexate chemotherapy for low-risk gestational trophoblastic tumor]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 25(4):414–417.
   Google Scholar
• Maestá I, Nitecki R, Horowitz NS, Goldstein DP, de Freitas Segalla Moreira M, Elias KM, Berkowitz RS. 2017. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience. Gynecol Oncol. 148(1):161–167.
   Web of Science ®Google Scholar
• Maria L, Tae KY. 2010. Revised International Federation of Gynecology and Obstetrics (FIGO) staging systems in gynecologic malignancies. Korean Journal of Obstetrics & Gynecology. 53(8):669.
   Google Scholar
• Mathew RA, Johnson S, Jose S, Chakraborty S, Kenneth N, Gowda V. 2018. A comparative study of monotherapy versus combination therapy in patients with stage-1 hypertension in terms of efficacy and cost effectiveness and to assess the medication adherence. Int J Res Pharm Sci. 9(1):147–153.
   Google Scholar
• Matsui H, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, Sekiya S. 2005. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol. 96(3):616–620.
   Web of Science ®Google Scholar
• Mei P, Ding Y, Ling Y, Deng Y, Lai W, Yun H, Zhang H, Wu X, Hong F, Hui D. 2015. Tegafur substitution for 5-Fu in combination with actinomycin D to treat gestational trophoblastic neoplasm. Plos One. 10(11):e0143531.
   Web of Science ®Google Scholar
• Ngan HY. 2010. The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int J Gynecol Cancer. 14(2):202–205.
   Google Scholar
• Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez SA, Kelley JL, Provencher D, Scott MD, Covens AL, Lage JM. 2015. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 29(7):825–831.
   Google Scholar
• Savage P, Cooke R, Onions J, Krell J, Kwan A, Camarata M, Dancy G, Short D, Seckl MJ, Swerdlow AJ. 2015. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol. 33(5):472–478.
   PubMed Web of Science ®Google Scholar
• Shahbazian N, Razi T, Razi S, Yazdanpanah L. 2014. Comparison of the efficacy of methotrexate and actinomycin D in the treatment of patients with stage I low risk gestational trophoblastic neoplasia (GTN). Med J Islam Repub Iran. 28(28):78–78.
   Google Scholar
• Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S, Shiozawa S. 2016. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. Arthritis Res Ther. 18(1):1–9.
   Google Scholar
• Shobeiri MJ, Vejdani R, Melli MS, Madarek EOS, Garebaghi PM, Khoei SA, Ghojazadeh M, Asgharzadeh A. 2014. Comparison of methotrexate-folinic acid versus pulsed actinomycin-d in treatment of stage i, low risk gestational trophoblastic neoplasia: a randomized clinical trial. Iran J Obstet Gynecol Infertil. 17(91):1–11.
   Google Scholar
• Sun N, Sun Q, Liu Q, Zhang T, Zhu Q, Wang W, Cao M, Zang QI. 2016. α-fetoprotein-producing gastric carcinoma: a case report of a rare subtype and literature review. Oncol Lett. 11(5):3101–3104.
   Web of Science ®Google Scholar
• Uberti EM, Fajardo MC, Da CA, Frota SS, Braga A, Ayub AC. 2015. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day methotrexate with folinic acid versus bolus-dose actinomycin-D, among Brazilian women. Rev Bras Ginecol Obstet. 37(6):258–265.
   PubMedGoogle Scholar
• Wang N, Gynaecology DO. 2016. The effect of intracavity ultrasound guided puncture ectopic pregnancy sac injection of methotrexate in treatment of ectopic pregnancy. China Cont Med Educ. 7(3):112–120.
   Google Scholar
• Wang Y, Miao JW, Wang T, Wang Y, Wu YM, Kong WM, Su L, Duan W. 2016. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia. J Chemother. 28(2):135–139.
   PubMed Web of Science ®Google Scholar
• Williams J, Short D, Dayal L, Strickland S, Harvey R, Tin T, Savage PM, Seckl MJ. 2014. Effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia. J Reprod Med. 59(5–6):248–254.
   Web of Science ®Google Scholar
• Xiao hua FU, Shi YF. 2003. Progress in study on the mechanism of multiple drug resistance in the treatment of gestational trophoblastic tumor. Foreign Med Sci. 5(3):113–123.
   Google Scholar
• Yang J, Xiang Y, Wan X, Feng F, Ren T. 2016. Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences. Gynecol Oncol. 143(1):68–72.
   PubMed Web of Science ®Google Scholar
• Yarandi F, Mousavi A, Abbaslu F, Aminimoghaddam S, Nekuie S, Adabi K, Hanjani P. 2016. Five-day intravascular methotrexate versus biweekly actinomycin-D in the treatment of low-risk gestational trophoblastic neoplasia: a clinical randomized trial. Int J Gynecol Cancer. 26(5):971–976.
   Web of Science ®Google Scholar
• Zhu J. 2015. 2 regimens for the treatment of high-risk gestational trophoblastic tumor and drug resistance related factors. China Pharm. 8(13):313–319.
   Google Scholar